On November 10, 2025, Bristol-Myers Squibb completed a public offering of €4.9 billion in various notes, with interest rates ranging from 2.973% to 4.581%, intended to fund a tender offer and general corporate purposes. The offering was initiated on October 31, 2025, and includes notes maturing from 2030 to 2055.